# Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

> **NCT04645212** · — · ACTIVE_NOT_RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** ADVM-022

## Key facts

- **NCT ID:** NCT04645212
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-14
- **Primary completion:** 2030-06-26
- **Final completion:** 2030-06-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645212, "Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04645212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*